GM2 Gangliosidosis AB Variant · GM2A-related gangliosidosis · GM2 Activator Protein Deficiency · Tay-Sachs Disease AB Variant · GM2-Gangliosidose AB-Variante
This is an inherited metabolic disorder where a deficiency in a specific activator protein prevents the body from breaking down certain lipid-sugar compounds. Because these compounds cannot be recycled, they build up to toxic levels inside the cells of the brain and nervous system. This accumulation causes progressive and severe damage to these vital tissues.
Symptoms typically begin in early puppyhood, usually at just a few months of age. Owners will notice rapidly worsening signs such as movement difficulties, tremors, muscle weakness, and eventual blindness.
There is no cure for this fatal condition, and treatment is limited to supportive care to maintain comfort. Palliative care and eventual humane euthanasia typically cost between 500 and 2500 EUR.
Estimated range of typical treatment cost. Actual cost depends on severity, clinic and region.
More conditions affecting the Head / nervous system.